US Patent

US8895058 — Low dose topiramate/phentermine composition and methods of use thereof

Formulation · Assigned to Vivus LLC · Expires 2028-06-09 · 2y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a low-dose composition of topiramate and phentermine for weight loss and treating obesity-related conditions.

USPTO Abstract

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.

Drugs covered by this patent

Patent Metadata

Patent number
US8895058
Jurisdiction
US
Classification
Formulation
Expires
2028-06-09
Drug substance claim
No
Drug product claim
Yes
Assignee
Vivus LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.